Related references
Note: Only part of the references are listed.AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells
Shanshan Pei et al.
CELL STEM CELL (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoidderived hematologic malignancies
Stephen E. Kurtz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
Kyung-Min Lee et al.
CELL METABOLISM (2017)
SynergyFinder: a web application for analyzing drug combination dose-response matrix data
Aleksandr Ianevski et al.
BIOINFORMATICS (2017)
Therapeutic targeting of acute myeloid leukemia stem cells
Daniel A. Pollyea et al.
BLOOD (2017)
Evolution of acute myelogenous leukemia stem cell properties after treatment and progression
Tzu-Chieh Ho et al.
BLOOD (2016)
Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells
Shanshan Pei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Stanley W. K. Ng et al.
NATURE (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Three-minute method for amino acid analysis by UHPLC and high-resolution quadrupole orbitrap mass spectrometry
Travis Nemkov et al.
AMINO ACIDS (2015)
AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress
Shrivani Sriskanthadevan et al.
BLOOD (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
Alicia Cole et al.
CANCER CELL (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model
Bhagwan Yadav et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
James M. Bogenberger et al.
LEUKEMIA & LYMPHOMA (2015)
Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials
Daniel A. Pollyea et al.
HAEMATOLOGICA (2014)
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
J. M. Bogenberger et al.
LEUKEMIA (2014)
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Liran I. Shlush et al.
NATURE (2014)
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale et al.
NATURE (2014)
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Rongqing Pan et al.
CANCER DISCOVERY (2014)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
El-ad David Amir et al.
NATURE BIOTECHNOLOGY (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia
Marko Skrtic et al.
CANCER CELL (2011)
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R gamma c-deficient mice
Jean-Emmanuel Sarry et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Stem cell gene expression programs influence clinical outcome in human leukemia
Kolja Eppert et al.
NATURE MEDICINE (2011)
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)
Marina Konopleva et al.
CANCER RESEARCH (2008)
Mitochondrial complex II in the post-ischemic heart - Oxidative injury and the role of protein S-glutathionylation
Yeong-Renn Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Mechanisms of disease - Cancer stem cells
Craig T. Jordan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
A van Rhenen et al.
CLINICAL CANCER RESEARCH (2005)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)